Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

567
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
567
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

584
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
584
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

457
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
457
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

438
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
438
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

554
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
554
Other Pulmonary Disorders01:17

Other Pulmonary Disorders

1.5K
Respiratory disorders encompass a range of conditions with varying levels of severity. Asthma, marked by chronic airway inflammation and hypersensitivity, is one such condition. It can lead to airway obstruction due to factors like bronchial spasms, mucosal edema, increased mucus secretion, or epithelial damage. Asthma triggers are diverse, ranging from allergens to emotional upset, and treatment focuses on both immediate relief through bronchodilators and long-term inflammation suppression.
1.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Topics in Lung Disease: Pulmonary Nodules.

FP essentials·2026
Same author

Topics in Lung Disease: Obesity-Hypoventilation Syndrome.

FP essentials·2026
Same author

Topics in Lung Disease: Noninfectious Pleural Effusions.

FP essentials·2026
Same author

Contextualizing COVID-19 Vaccine Hesitancy in the Broader Vaccination Debate.

PRiMER (Leawood, Kan.)·2025
Same author

Strategies for Sustained Empowerment of Community Health Workers: A Qualitative Analysis of the Comprehensive Rural Health Project in Jamkhed, India.

Inquiry : a journal of medical care organization, provision and financing·2024
Same author

Changes in prenatal care and vaccine willingness among pregnant women during the COVID-19 pandemic.

BMC pregnancy and childbirth·2022

Related Experiment Video

Updated: Jan 15, 2026

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
08:08

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets

Published on: May 11, 2015

14.5K

Topics in Lung Disease: Pulmonary Hypertension.

Alexander Kaysin1, Sunil Swami2, Oluwatoni Aluko2

  • 1University of Maryland (UM) Capital Region Health Family Medicine Residency Program in Largo, MD.

FP Essentials
|January 13, 2026
PubMed
Summary

Pulmonary hypertension (PH) is a serious condition diagnosed via echocardiography and right heart catheterization. Early prevention and targeted therapies, including novel pharmacotherapies, improve patient outcomes.

More Related Videos

Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat
08:34

Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat

Published on: November 18, 2018

7.6K
A Model of Reverse Vascular Remodeling in Pulmonary Hypertension Due to Left Heart Disease by Aortic Debanding in Rats
07:41

A Model of Reverse Vascular Remodeling in Pulmonary Hypertension Due to Left Heart Disease by Aortic Debanding in Rats

Published on: March 1, 2022

3.4K

Related Experiment Videos

Last Updated: Jan 15, 2026

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
08:08

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets

Published on: May 11, 2015

14.5K
Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat
08:34

Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat

Published on: November 18, 2018

7.6K
A Model of Reverse Vascular Remodeling in Pulmonary Hypertension Due to Left Heart Disease by Aortic Debanding in Rats
07:41

A Model of Reverse Vascular Remodeling in Pulmonary Hypertension Due to Left Heart Disease by Aortic Debanding in Rats

Published on: March 1, 2022

3.4K

Area of Science:

  • Cardiology
  • Pulmonology
  • Internal Medicine

Background:

  • Pulmonary hypertension (PH) is a progressive disorder marked by high pulmonary artery pressure.
  • Early diagnosis relies on recognizing symptoms like dyspnea and fatigue, with echocardiography as a primary tool.

Purpose of the Study:

  • To outline diagnostic criteria for PH, including echocardiography and right heart catheterization.
  • To detail primary and secondary prevention strategies for PH.
  • To review current and emerging pharmacotherapies for pulmonary arterial hypertension (PAH).

Main Methods:

  • Diagnosis confirmed by right heart catheterization (mean pulmonary artery pressure ≥20 mm Hg, pulmonary vascular resistance >2 Wood units).
  • Prevention strategies encompass lifestyle modifications, risk factor control (hypertension, diabetes), and environmental exposure management.
  • Pharmacotherapy review includes targeting endothelin, prostacyclin, and nitric oxide pathways.

Main Results:

  • Advances in pharmacotherapy targeting specific pathways have enhanced outcomes for pulmonary arterial hypertension.
  • Combination therapy is advised for moderate-to-severe disease; parenteral prostanoids are for advanced PAH.
  • Management of right-sided heart failure involves fluid management, diuretics, and consideration of lung transplantation or palliative procedures.

Conclusions:

  • Effective management of pulmonary hypertension requires early suspicion, accurate diagnosis, and comprehensive prevention strategies.
  • Novel pharmacotherapies offer improved outcomes, with combination therapy and advanced treatments tailored to disease severity.
  • Integrated supportive care, including nutrition and management of complications like right-sided heart failure, is crucial for PH patients.